Supplementary Material

Details of data collection

A data collection firm (WeConsult) performs the in-country coordination of participant enrollment, data collection, and sample collection. Enumerators are recruited from Beira; all are fluent in Portuguese (spoken by >80% of the study population)¹ and more than half speak the local language. Enumerators conduct household visits for consent and eligibility pre-birth, and at months 3, 6, 9, and 12 post-birth; active surveillance calls take place monthly (**Figure 4**). All data are collected on electronic tablets using Open Data Kit (ODK) Collect, an open source program which allows offline data collection on a mobile device.²

2.4.1. Household visit

Survey instruments consist of several modules aimed at collecting data on key indicators through structured observations, reports from respondents, and objective measurements (Table S1). The survey includes household questions (e.g., SES, demographics, nutrition and food insecurity, flooding, animals, and sanitation and handwashing facilities), questions about the mothers (e.g., demographics, medical and physical health, pregnancy and birth care, and breastfeeding practices), questions about the index child (e.g., birth outcome, nutrition, health and recent illness, anthropometry, and vaccination history), and household questions about drinking water. We also collect GPS coordinates at each household visit.

2.4.2. Active surveillance calls

A brief monthly active surveillance call is conducted by phone to gather information on prenatal and perinatal environmental exposures and illnesses, on child illness symptoms, and intake of medicines, vitamins, breastfeeding, and introduction of complementary foods. The first active surveillance pre-birth call is targeted to occur one month after enrollment and calls continue on a monthly basis between visits. To facilitate communication with the study team participants receive a 150 MZN phone credit at each visit.

2.4.3. Drinking water

Drinking water characteristics, which are on the causal pathway between the intervention and our study outcomes (**Figure 1**), will be used to provide evidence of biological plausibility of the intervention's effects on these downstream outcomes. We will characterize water access using the Joint Monitoring Program definition of "safely managed," i.e., an improved water source that is accessible on premises (located within the dwelling, yard or plot), available when needed (sufficient water available for at least 12 hours per day), and free from contamination (no *E. coli* detected in a 100mL sample).^{3,4} We also assess a number of additional variables related to drinking water, including aspects of water quality, water access, water availability, water security, water consumption, and participant satisfaction with water. These variables are evaluated throughout the study at the household level and also at the community level through objective, observed, and participant-reported measures.

2.4.4. Diarrhea

At months 3, 6, 9, and 12, we ask the caregiver to report diarrhea and blood in the stool (dysentery) of the index child in the previous week. We use the case definition of diarrhea as 3 or more loose stools in a 24 hour period.⁵ Due to concerns about reporting biases, we also include a negative control outcome⁶; caregivers report on accidents that resulted in physical injury in the previous week. In addition, we note objective characteristics of the stool samples collected, including observed blood and mucus and an infant stool form scale describing consistency (4-point scale), amount (4-point scale), and color (6 categories).⁷

2.4.5. Anthropometry

At months 3, 6, 9, and 12, we measure child: 1) length, weight, and head circumference. From these measures we will calculate Z-scores (LAZ and WAZ), and prevalence of stunting and underweight, defined

as two standard deviations below median of the reference population.⁸ We measure weight using digital baby weighing scales with 5g gradations (ADE, Model# M112600, Hamburg, Germany), and we measure height using a baby length measuring board with 1mm gradations (ADE, Model# MZ10040).⁹ Measurements are repeated twice and recorded into the survey. The enumerator is prompted to conduct a third measurement if there are differences of >1 cm in length or head circumference or if weight is off by >0.5kg in the two repeated measurements. Each child's LAZ and WAZ will be calculated using the WHO Child Growth Standards for the reference population^{10,11} and WHO Anthropometric macros.¹²

Details of sample collection, processing, and analysis

2.5.1. Stool

Sample collection: Stool of the index child is collected at months 3, 6, 9, and 12 using a diaper, which is provided to the primary caregiver before a household visit. If a fecal sample is not provided during the initial home visit, we leave the primary caregiver with additional diapers and two more attempts are made to collect the sample within 4 hours of production. If needed, we provide a cooler and cold-pack, and collect the sample within 7 hours of production.

Sample processing: Lab personnel transfer 1g fecal material from the diaper into a DNA/RNA Shield Fecal Collection Tube (Zymo Research, Irvine, CA, USA); we aim to collect three aliquots in separate collection tubes. The DNA/RNA Shield stabilization buffer lyses the cells and renders the sample DNA and RNA stable for 30 days at ambient temperature.¹³ Samples are stored and shipped at -20 °C. Nucleic acids are extracted from fecal samples using the QIAamp 96 Virus QIAcube HT Kit on a QIAcube HT (Qiagen Sciences Inc., Germantown, MD, USA), and stored at -80°C until further processing.

Analysis - parasites: Immediately after the first three aliquots are placed in the collection tubes, two additional aliquots of fecal material are taken from the diaper to prepare a slide for Kato-Katz analysis of parasite ova¹⁴. If sufficient material is available for a second slide analysis is carried out in duplicate. Samples are analyzed for hookworm (*e.g., Necator americanus, Ancylostoma duodenale*) immediately following slide preparation, and for Ascaris spp., Schistosoma mansoni, Trichuris trichiura, Taenia, Enterobius vermicularis, and Strongyloides stercoralis after overnight incubation at room temperature. Eligible participants are referred for deworming medicine at the 12-month visit, after returning results of the parasitological exam to study subjects in collaboration with Instituto Nacional de Saude (INS) staff in Beira.

Analysis - enteric pathogens: Extracted nucleic acids are analyzed using the TaqMan Array card (TAC, ThermoFisher Scientific, Waltham, MA, USA) assay, which allows quantification by real-time PCR via a 384-well microfluidic card for simultaneous detection of multiple viral, bacterial, and parasitic enteric pathogen targets as well as antimicrobial resistance genes. Immediately prior to nucleic acid extraction, samples used in downstream TAC assays are seeded with the Inforce 3 Bovine Vaccine (Zoetis, Parsippany-Troy Hills, NJ, USA)¹⁵ containing Bovine Herpesvirus 1 (BHV) and Bovine Respiratory Syncytial Virus (BRSV) as extrinsic controls, to monitor extraction and amplification efficiency. Pathogens will be linked to the diarrheal disease episode based on relative cycle threshold values from the TaqMan results.¹⁶ The specific targets we will test for are shown in **Table S2**. The batch of TaqMan Array Cards will be QA/QC using positive control plasmids. Initially, a standard curve for quantification will be run in duplicate, and the limit of detection and limit of quantification will be determined by running cards at a low concentration (concentration determined based on the standard curve tests) until a 95% positivity rate out of at least ten assays is obtained. Additionally, when processing samples, standard curves will be run in singlicate once per month with the positive control plasmid. A negative control will be run per card.

Analysis - Gut microbiome composition: We will characterize the gut microbial community structure and composition by sequencing of the V4 region of the 16S ribosomal RNA (rRNA) gene amplicon. Immediately prior to nucleic acid extraction, samples used in downstream 16s assays will be seeded with the ZymoBIOMICS Spike-in Control I (High Microbial Load) (Zymo Research) containing *Imtechella*

halotolerans and *Allobacillus halotolerans*. Bioinformatic analyses will be completed using the QIIME2 software platform and other bioinformatics tools¹⁷.

2.5.2. Dried blood spots

Sample collection: A trained nurse collects up to six dried spots of capillary blood of the index child at 6, 9, and 12 month visits on Tropbio Filter Paper Blood Collection Disks (Cellabs, Sydney, Australia), using a 2mm lancet.

Sample processing: Samples are allowed to dry overnight, then three aliquots of two spots each are placed in a Ziploc bag with silica desiccant. Dried blood spots can be stored at ambient temperatures for up to 100 days, even in tropical climates^{18,19} but samples are stored at -20 °C and shipped at ambient temperature.²⁰

Analysis – antibodies: We will use the Luminex platform to carry out high throughput, multiplex antibody assays that enable the simultaneous measurement of quantitative antibody responses to dozens of pathogens from a single blood spot.²¹ Bead coupling of antigens will occur at the U.S. Centers for Disease Control and Prevention (CDC), and CDC collaborators will also provide support in determining appropriate antigen cut points. Our panel includes a subset of enteropathogens that have targets on the TAC assay, including *Giardia, Cryptosporidium, Entamoeba histolytica*, norovirus, *Campylobacter*, enterotoxigenic *E. coli* and *V. cholerae*, following previous similar studies.²² Our first measure will occur at 6 months, to avoid detection of maternal antibodies that wane over the first 3-6 months of life. ²³

2.5.3. Drinking water

Sample collection: We collect 100-mL household drinking water samples from source and stored water at all household visits. We select the drinking water source sample by asking the mother what the source of water is for the household that would be given to the study child to drink, or to mix formula. If the source water is not in the household, the enumerator walks with the mother to the source (e.g., a neighbor's house or public standpipe) to collect a sample and GPS location. We select the stored water sample by asking the mother for any water in the household that is used for drinking purposes; stored water is water stored in a jerry can, bucket, or other container in the household for later consumption.

To complement the household sampling, we also collect samples from a selection of 45 public standpipes located within the study area and 55 additional public standpipes located elsewhere in the city of Beira. At public standpipes we also measure water pressure by measuring time to fill a fixed volume (1L or 5L, depending on the pressure).

Sample processing and analysis: All samples are placed on cold packs after collection for transport to a lab in Beira. Samples are processed for fecal indicator bacteria within six hours of collection using Colilert-18 reagent and the Quanti-Tray/2000 MPN method (IDEXX Laboratories, Westbrook, ME, USA). Free and total chlorine levels are measured using a DR300 Pocket Colorimeter (Hach Company, Loveland, CO, USA) and DPD powder pillows (Hach Company)²⁴. Additional physiochemical parameters (pH, conductivity, and turbidity) are measured for public standpipe water samples using a Pocket Pro+ Multi 2 Tester and TL2300 turbidity meter (Hach Company).

Details of Blinding

At enrollment, households are assigned a unique identifier independent of intervention status. The core data management team conducts quality assurance using geocoded data to ensure group exposure status aligns with cluster-level designations of the exposure (i.e., intervention vs control areas). All geocoded data and group exposure indicators are removed prior to an external analyst performing the data cleaning and primary analysis. Data are cleaned, including decisions on missing data, outliers, and variable categorizations, before the analyst receives any group exposure. The analyst performs the primary analyses making comparisons between undefined group exposures. Once the analysis models are finalized, these rehearsal results are input into tables to create table shells for the final analyses. The primary analyst then receives a

masking key, with true cluster-level designations of the exposure, and reruns the code with the appropriate group exposure, and re-inputs the final results into the table shells.

Table S1. Household survey data collection in the PAASIM Study

Category	Indicator	Time poir	nt _				Type of data	
		Pre-birth	3mo	6mo	9mo	12mo		
Household-level								
General	Socio-economic status	Х	*	*	*	Х	Respondent reported	
characteristics							Observation of households	
	Demographics (household ownership,	Х	*	*	*	Х	Respondent reported	
	household members, children under 5 years							
	of age, primary wage earner)							
Nutrition	Food insecurity	Х	Х	Х	Х	Х	Respondent reported	
	Types of food consumed by household						Respondent reported	
	members yesterday							
Sanitation	Access to improved sanitation	Х	Х	Х	Х	Х	Observation of household latrines	
	Location of sanitation facility	Х	Х	Х	Х	Х	Observation of household compounds	
	Sharing of sanitation facility	Х	Х	Х	Х	Х	Respondent reported	
	Sanitation facility characteristics	Х	Х	Х	Х	Х	Observation of household latrines	
	(serviceable, drop hole cover, smooth and							
	cleanable floor)							
	Presence of human feces in the household	Х	Х	Х	Х	Х	Observation of household compounds	
	compound							
	Trash disposal	Х	Х	Х	Х	Х	Respondent reported	
Handwashing	Access to handwashing facility with soap	Х	Х	Х	Х	Х	Observation of household compounds	
	and water							
Flooding	Flooding of household compound	Х	Х	Х	Х	Х	Respondent reported	
Animals	Presence of animals in the household or	Х	Х	Х	Х	Х	Respondent reported	
	compound (chickens, ducks/turkey, dogs,							
	cats, pigs, sheep, goats, rabbits, donkeys)							
	Presence of animal feces in the household	Х	Х	Х	Х	Х	Observation of household compounds	
	compound							
	Child(ren) contact with animals	Х	Х	Х	Х	Х	Respondent reported	
Health	Deworming history (pre-school age children,		Х	Х	Х	Х	Respondent reported	
	school age children, and mother)							
Moving	Moved to another household		Х	Х	Х	Х	Respondent reported	
							Observation of household compounds	

Notes: *Asked if study household has moved to another location within the study area

Category	Indicator	Time poi	nt				Type of data
		Pre-birth	3mo	6mo	9mo	12mo	
Mother-level							
General	Demographics (age, religion, language,	Х				Х	Respondent reported
characteristics	education, employment, marital status)						
Mental and	WHO 5 well-being index	Х	Х	Х	Х	Х	Respondent reported
physical health	Medical diagnosis history (diabetes, high	Х					Respondent reported
	blood pressure, heart disease, urinary tract						
	infection, kidney disease, sexually-						
	transmitted disease, cancer, malaria)						
	Vaginal health practices	Х					Respondent reported
	Pregnancy history	Х					Respondent reported
Pregnancy health	Expected delivery date	Х					Respondent reported
	Pre-natal care	Х					Respondent reported
	Medical diagnosis during pregnancy	Х					Respondent reported
	(gestational diabetes, high blood pressure,						
	placenta previa, COVID-19, Dengue, Zika,						
	Chikungunya, Malaria)						
	Medications, vitamins, or supplements	Х					Respondent reported
	during pregnancy						
Birth care	Delivery location		Х				Respondent reported
	Cesarean section		Х				Respondent reported
	Post-natal care		Х				Respondent reported
Breastfeeding	Breastfeeding intentions	Х					Respondent reported
	Breastfeeding practices		Х	Х	Х	Х	Respondent reported
Sanitation	Primary place of defecation in last week	Х	Х	Х	Х	Х	Respondent reported
	Exclusive use of sanitation facility in last	Х	Х	Х	Х	Х	Respondent reported
	week						
Travel	Estimated time spent away from home in					Х	Respondent reported
	the last 12 months						

Category	Indicator	Time poir	nt				Type of data
		Pre-birth	3mo	6mo	9mo	12mo	
Child-level							
Birth	Birth outcome		Х				Respondent reported
	Birthdate		Х				Observation of child health card
	Birth weight		Х				Respondent reported
	Sex		Х				Observation of child health card
Health	Mortality		Х	Х	Х	Х	Respondent reported
	Vaccination history (DTP, Rotavirus, Polio,		Х	Х	Х	Х	Observation of child health card
	MMR)						
	Medication history		Х	Х	Х	Х	Respondent reported
	Deworming history					Х	Respondent reported
	Illness (diarrhea, dysentery, nasal		Х	Х	Х	Х	Respondent reported
	congestion, fever, vomiting, physical injury)						
	in the last week						
	Medical diagnosis (colic, ear infection,		Х	Х	Х	Х	Respondent reported
	anemia, respiratory illness, malaria, asthma)						
	and treatment history						
Anthropometry	Head circumference		Х	Х	Х	Х	Objective measurement
	Body length		Х	Х	Х	Х	Objective measurement
	Body weight		Х	Х	Х	Х	Objective measurement
Nutrition	Types of liquid food consumed in the last		Х	Х	Х	Х	Respondent reported
	week						
	Types of solid food consumed in the last			Х	Х	Х	Respondent reported
	week						
Sanitation	Diaper wearing		Х	Х	Х	Х	Respondent reported
	Disposal of child stools		Х	Х	Х	Х	Respondent reported
Water consumption	Child consumption of drinking water source		Х	Х	Х	Х	Respondent reported
	Drinking water treatment for child		Х	Х	Х	Х	Respondent reported
	consumption						
Travel	Estimated time spent away from home in					Х	Respondent reported
	the last 12 months						

Category	Indicator	Time poi	nt				Type of data
		Pre-birth	3mo	6mo	9mo	12mo	
Drinking water-level							
Water access	Municipality water connection and status	Х	Х	Х	Х	Х	Observation of water meter
	Type of drinking water source	Х	Х	Х	Х	Х	Respondent reported
							Observation of water source
	Alternate source for non-drinking water	Х	Х	Х	Х	Х	Respondent reported
	Alternate source for drinking water outages	Х	Х	Х	Х	Х	Respondent reported
	Distance to water main	Х	Х	Х	Х	Х	GPS location
	Location of drinking water source	Х	Х	Х	Х	Х	Respondent reported
	Distance to drinking water source	Х	Х	Х	Х	Х	GPS location
	Time to collect water (minutes for round trip	Х	Х	Х	Х	Х	Respondent reported
	and trips per week)						
Water availability	Water availability (hours per day and days	Х	Х	Х	Х	Х	Respondent reported
	per week)						
	Household water storage (large and small	Х	Х	Х	Х	Х	Respondent reported
	containers)						
	Piped water flow rate (liters per minute)	Х	Х	Х	Х	Х	Objective measurement
	Water availability at handwashing facility	Х	Х	Х	Х	Х	Observation of handwashing facility
	Water availability at sanitation facility	Х	Х	Х	Х	Х	Observation of sanitation facility
Drinking water	Treatment of stored water	Х	Х	Х	Х	Х	Respondent reported
quality	Drinking water free/total chorine (source	Х	Х	Х	Х	Х	Objective measurement
	and stored water)						
Water security	Sharing of water connection	Х	Х	Х	Х	Х	Respondent reported
	Household water insecurity experiences	Х	Х	Х	Х	Х	Respondent reported
	Sufficient quantity of drinking water	Х	Х	Х	Х	Х	Respondent reported
User satisfaction	Satisfied with water service	Х	Х	Х	Х	Х	Respondent reported
with water	Satisfied with water availability	Х	Х	Х	Х	Х	Respondent reported
	Satisfied with water pressure	Х	Х	Х	Х	Х	Respondent reported
	Satisfied with water color and appearance	Х	Х	Х	Х	Х	Respondent reported
	Satisfied with water taste and smell	Х	Х	Х	Х	Х	Respondent reported
	Satisfied with water affordability	Х	Х	Х	Х	Х	Respondent reported
Water consumption	Monthly water expenses	Х	Х	Х	Х	Х	Respondent reported
	Water usage (liters per day)	Х	Х	Х	Х	Х	Respondent reported
							Observation of water meter

Table S2: Targets Assayed by the TaqMan Array Card (TAC) for the PAASIM study

Target	Gene of interest Forward (5' to 3') Reverse (5' to 3')		Probe (5' to 3')*		
		Bacterial	Pathogens		
Enteroaggregative E.	aaiC	ATTGTCCTCAGGCATTTCAC	ACGACACCCCTGATAAACAA	TAGTGCATACTCATCATTTAAG	
coli (EAEC)	aatA	CTGGCGAAAGACTGTATCAT	TTTTGCTTCATAAGCCGATAGA	TGGTTCTCATCTATTACAGACAGC	
Diarrheagenic <i>E. coli</i> (DAEC)	afaB	GTCTCCCTGAATGTACAGCTTTCA	CMCTCTGCCACTCCACCTT	TCAAGCTGTTTGTTCGTC	
Shiga toxin-producing	stx1	ACTTCTCGACTGCAAAGACGTATG	ACAAATTATCCCCTGWGCCACTATC	CTCTGCAATAGGTACTCCA	
E. coli (STEC)	stx2	CCACATCGGTGTCTGTTATTAACC	GGTCAAAACGCGCCTGATAG	TTGCTGTGGATATACGAGG	
Enteropathogenic E.	eae	CATTGATCAGGATTTTTCTGGTGATA	CTCATGCGGAAATAGCCGTTA	ATACTGGCGAGACTATTTCAA	
coli (EPEC)	bfpA	TGGTGCTTGCGCTTGCT	CGTTGCGCTCATTACTTCTG	CAGTCTGCGTCTGATTCCAA	
	LT	TTCCCACCGGATCACCAA	CAACCTTGTGGTGCATGATGA	CTTGGAGAGAAGAACCCT	
Enterotoxigenic E. coli (FTEC)	STh	GCTAAACCAGCAGGGTCTTCAAAA	CCCGGTACAAGCAGGATTACAACA	TGGTCCTGAAAGCATGAA	
(1120)	STp	TGAATCACTTGACTCTTCAAAA	GGCAGGATTACAACAAAGTT	TGAACAACACATTTTACTGCT	
<i>Shigella</i> spp./ Enteroinvasive <i>E. coli</i> (<i>EIEC</i>)	іраН	CCTTTTCCGCGTTCCTTGA	CGGAATCCGGAGGTATTGC	CGCCTTTCCGATACCGTCTCTGCA	
E. coli O157	rbdE	TTTCACACTTATTGGATGGTCTCAA	CGATGAGTTTATCTGCAAGGTGAT	CTCTCTTTCCTCTGCGGTCCT	
Campylobacter jejuni/ C. coli	cadF	CTGCTAAACCATAGAAATAAAATTTCTCAC	CTTTGAAGGTAATTTAGATATGGATAATCG	CATTTTGACGATTTTTGGCTTGA	
Salmonella spp.	ttr	CTCACCAGGAGATTACAACATGG	AGCTCAGACCAAAAGTGACCATC	CACCGACGGCGAGACCGACTTT	
Vibrio cholerae	hylA	ATCGTCAGTTTGGAGCCAGT	TCGATGCGTTAAACACGAAG	ACCGATGCGATTGCCCAA	
Clostridium difficile	tcdB	GGTATTACCTAATGCTCCAAATAG	TTTGTGCCATCATTTTCTAAGC	CCTGGTGTCCATCCTGTTTC	
		Viral Pa	thogens		
Adenovirus	fiber	AACTTTCTCTCTTAATAGACGCC	AGGGGGCTAGAAAACAAAA	CTGACACGGGCACTCT	
Astrovirus	capsid	CAGTTGCTTGCTGCGTTCA	CTTGCTAGCCATCACACTTCT	CACAGAAGAGCAACTCCATCGC	
Hepatitis G	5' UTR	CGGCCAAAAGGTGGT GGA TG	CGACGAGCCTGACGTCGGG	AGGTCCCTCTGGCGCTTGTGGCGAG	
Norovirus GI	ORF1-ORF2	CGCTGGATGCGATTCCATGA	CTTAGACGCCATCATCATTTAC	TGGACAGGAGATCGC	
Norovirus GII	ORF1-ORF2	CAAGAACCTATGTTTAGATGGATGAG	TCGACGCCATCTTCATTCACA	TGGGAGGGCGATCGCAATCT	
Rotavirus	NSP3	ACCATCTWCACRTRACCCTCTATGAG	GGTCACATAACGCCCCTATAGC	AGTTAAAAGCTAACACTGTCAAA	
Sapovirus	RdRp	GAYCASGCTCTCGCYACCTAC	CCCTCCATYTCAAACACTA; TTGGCCCTCGCCACCTAC	CCRCCTATRAACCA	
SARS-CoV-2	N1	GACCCCAAAATCAGCGAAAT	TCTGGTTACTGCCAGTTGAATCTG	ACCCCGCATTACGTTTGGTGGACC	

Target	Gene of interest Forward (5' to 3')		Reverse (5' to 3')	Probe (5' to 3')*	
		Protozoan	pathogens		
Cryptosporidium spp.	18S rRNA	GGGTTGTATTTATTAGATAAAGAACCA	AGGCCAATACCCTACCGTCT	TGACATATCATTCAAGTTTCTGAC	
Giardia duodenalis	18S rRNA	GACGGCTCAGGACAACGGTT	TTGCCAGCGGTGTCCG	CCCGCGGCGGTCCCTGCTAG	
Entamoeba histolytica	18S rRNA	ATTGTCGTGGCATCCTAACTCA	GCGGACGGCTCATTATAACA	TCATTGAATGAATTGGCCATTT	
Cyclospora					
cayetanensis	18S rRNA	AAAAGCTCGTAGTTGGATTTCTG	AACACCAACGCACGCAGC	AAGGCCGGATGACCACGA	
		Helminthic	pathogens		
Ascaris lumbricoides	ITS1	GCCACATAGTAAATTGCACACAAAT	GCCTTTCTAACAAGCCCAACAT	TTGGCGGACAATTGCATGCGAT	
Trichuris trichiura	18S rRNA	TTGAAACGACTTGCTCATCAACTT	CTGATTCTCCGTTAACCGTTGTC	CGATGGTACGCTACGTGCTTACCATGG	
Ancylostoma duodenale	ITS2	GAATGACAGCAAACTCGTTGTTG	ATACTAGCCACTGCCGAAACGT	ATCGTTTACCGACTTTAG	
Necator americanus	ITS2	CTGTTTGTCGAACGGTACTTGC	ATAACAGCGTGCACATGTTGC	CTGTACTACGCATTGTATAC	
		Antimicrobial re	esistance genes		
intl1		GATCGGTCGAATGCGTGT	GCCTTGATGTTACCCGAGAG	ATTCCTGGCCGTGGTTCTGGGTTTT	
mcr-1		GATCGCTGTCGTGCTCTTTG	ACCGCGCCCATGATTAATAG	CGATGCTACTGATCACCACG	
SHV		TCCCATGATGAGCACCTTTAAA	TCCTGCTGGCGATAGTGGAT	TGCCGGTGACGAACAGCTGGAG	
TEM		GCATCTTACGGATGGCATGA	GTCCTCCGATCGTTGTCAGAA	CAGTGCTGCCATAACCATGAGTGA	
CTX-M1		CCGTCACGCTGTTRTTAGGA	AATGCCACMCCCAGYCKKCC	CAGCAAAAACTTGCCGRATT	
CTX-M8-M25		ATRACACSTTCCGGCTCGAT	GCTAAYGGCGTGGTGGTATC	TCAACACCGCGATCCCCG	
CTX-M2-M74		GCGCAGACCCTGAAAAAYCT	TGYGCSCGCTGRGTTTCC	ACSCTGGGYAAAGCGC	
CTX-M9		GCTTTATGCGCAGACGARTG	ATCACCGCGATAAAGCACCT	TCGATACCRMAGATAATACGC	
KPC		GGCCGCCGTGCAATAC	GCCGCCCAACTCCTTCA	TGATAACGCCGCCGCCAATTTGT	
NDM		ATATCACCGTTGGGATCGAC	TAGTGCTCAGTGTCGGCATC	AAGGACAGCAAGGCCAAGTCG	
VIM		TSTACCCRTCCAATGGTCTC	AGAAGKGCCRCTGTGTTTTT	TGTCCGTGATGGYGATGAGTTG	
		Cont	rols		
16S		TGCAAGTCGAACGAAGCACTTTA	GCAGGTTACCCACGCGTTAC	CGCCACTCAGTCACAAA	
human mtDNA		CAATGAATCTGAGGAGGCTAC	CGTGCAAGAATAGGAGGTG	ACCCTCACACGATTCTTTACCTTTCACT	
BHV		GAGCAAAGCCCCGCCGAAGGA	TACGAACAGCAGCACGGGCGG	GAACCTGCCCACGCGCTGAAAC	
BRSV		GCAATGCTGCAGGACTAGGTATAAT	ACACTGTAATTGATGACCCCATTCT	ACCAAGACTTGTATGATGCTGCCAAAGCA	
	N 4 a a tha T / a a d	Land MCD an the 2' and			

*All probes have FAM on the 5' end and MGB on the 3' end

Table S3: Details of Power Calculations

The table below details our minimum detectible effect for individual and groups of pathogens given the control group prevalence (p1) ranging from 10% to 80%. It generates the minimum detectible effect as a risk ratio (delta) and resulting minimum detectible prevalence in the comparison group.

Our assumptions are the number of sub-neighborhoods in the intervention and comparison (M1/M2), average number of households enrolled per sub-neighborhood in intervention and control (K1/K2), standard alpha (0.05) and power (.80). We estimate the minimum detectible effect for three values of for the intra-class correlation coefficient, representing low, moderate and high clustering ($\rho = .01, 0.05, 0.1$). Our power calculations rely on the moderate estimates for ICC. We account for clustering at the sub-neighborhood level.

We apply the following code using STATA v16:

power twoproportions (.2(.05).8), cluster effect(ratio) m1(36) m2(26) k1(8) k2(10) power(.8) alpha(.05) direction(lower) rho(.01/.5/.1)

+ alpha	power	к1	к2	M1	M2	delta	p1	p2	rho
.05	.8	8	10	36	26	.5120	.2	.1024	.01
.05	.8	8	10	36	26	.5676	.25	.1419	.01
.05	.8	8	10	36	26	.6114	.3	.1834	.01
.05	.8	8	10	36	26	.6476	.35	.2266	.01
.05	.8	8	10	36	26	.6785	.4	.2714	.01
.05	.8	8	10	36	26	.7058	.45	.3176	.01
.05	.8	8	10	36	26	.7302	.5	.3651	.01
.05	.8	8	10	36	26	.7527	.55	.414	.01
.05	.8	8	10	36	26	.7736	.6	.4642	.01
.05	.8	8	10	36	26	.7935	.65	.5158	.01
.05	.8	8	10	36	26	.8127	.7	.5689	.01
.05	.8	8	10	36	26	.8317	.75	.6238	.01
.05 +	.8	8	10	36	26	.8509	.8	.6807	.01
.05	.8	8	10	36	26	.3585	.2	.07169	.05
.05	.8	8	10	36	26	.4262	.25	.1066	.05
.05	.8	8	10	36	26	.4804	.3	.1441	.05
.05	.8	8	10	36	26	.5257	.35	.184	.05
.05	.8	8	10	36	26	.5648	.4	.2259	.05
.05	.8	8	10	36	26	.5994	.45	.2698	.05
.05	.8	8	10	36	26	.6308	.5	.3154	.05
.05	.8	8	10	36	26	.6596	.55	.3628	.05
.05	.8	8	10	36	26	.6867	.6	.412	.05
.05	.8	8	10	36	26	.7126	.65	.4632	.05
.05	.8	8	10	36	26	.7376	.7	.5163	.05
.05	.8	8	10	36	26	.7624	.75	.5718	.05
.05 +	.8	8	10	36	26	.7875	.8	.63	.05
.05	.8	8	10	36	26	.5398	.5	.2699	.1
.05	.8	8	10	36	26	.5737	.55	.3155	.1
.05	.8	8	10	36	26	.6056	.6	.3634	.1
.05	.8	8	10	36	26	.6362	.65	.4135	.1
.05	.8	8	10	36	26	.6660	.7	.4662	.1
.05	.8	8	10	36	26	.6955	.75	.5216	.1
.05	.8	8	10	36	26	.7254	.8	.5804	.1
.05	.8	8	10	36	26	.7567	.85	.6432	.1
.05	.8	8	10	36	26	.7907	.9	.7117	.1

References Cited

- United Nations. The Mozambique third population and housing census [Internet]. 2007. Available from: http://unstats.un.org/unsd/demographic/sources/census/country_impl.htm
- Hartung C, Lerer A, Anokwa Y, Tseng C, Brunette W, Borriello G. Open data kit: tools to build information services for developing regions. In: Proceedings of the 4th ACM/IEEE International Conference on Information and Communication Technologies and Development - ICTD '10 [Internet]. London, United Kingdom: ACM Press; 2010 [cited 2022 Apr 20]. p. 1–12. Available from: http://dl.acm.org/citation.cfm?doid=2369220.2369236
- United Nations Children's Fund and World Health Organization. Integrating Water Quality Testing into Household Surveys: Thematic report on drinking water. New York: UNICEF and WHO; 2020.
- WHO UNICEF Joint Monitoring Programme. JMP methodology: 2017 update & SDG baselines [Internet]. Geneva: WHO & UNICEF; 2018 [cited 2020 Mar 10]. Available from: https://washdata.org/sites/default/files/documents/reports/2018-04/JMP-2017-updatemethodology.pdf
- 5. Levine GA, Walson JL, Atlas HE, Lamberti LM, Pavlinac PB. Defining Pediatric Diarrhea in Low-Resource Settings. J Pediatr Infect Dis Soc. 2017 Sep 1;6(3):289–93.
- 6. Arnold BF, Ercumen A. Negative Control Outcomes. JAMA. 2016 Dec 27;316(24):2597–8.
- 7. Bekkali N, Hamers SL, Reitsma JB, Van Toledo L, Benninga MA. Infant Stool Form Scale: Development and Results. J Pediatr. 2009 Apr 1;154(4):521-526.e1.
- 8. UNICEF. Nutrition: definitions of the indicators [Internet]. [cited 2015 Feb 5]. Available from: http://www.unicef.org/infobycountry/stats_popup2.html
- 9. Kotloff KL, Blackwelder WC, Nasrin D, Nataro JP, Farag TH, van Eijk A, et al. The Global Enteric Multicenter Study (GEMS) of diarrheal disease in infants and young children in developing countries: epidemiologic and clinical methods of the case/control study. Clin Infect Dis. 2012 Dec;55 Suppl 4:S232-45.
- 10. De Onis M. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva, Switzerland: World Health Organization; 2006.
- 11. World Health Organization. WHO child growth standards, SAS macros. Geneva, Switzerland: World Health Organization; 2010.
- World Health Organization. Child growth standards: WHO Anthro (version 3.2.2, January 2011) and macros [Internet]. 2016 [cited 2017 Feb 5]. Available from: http://www.who.int/childgrowth/software/en/

- 13. Kazantseva J, Malv E, Kaleda A, Kallastu A, Meikas A. Optimisation of sample storage and DNA extraction for human gut microbiota studies. BMC Microbiol. 2021 May 29;21(1):158.
- 14. Bosch F, Palmeirim MS, Ali SM, Ame SM, Hattendorf J, Keiser J. Diagnosis of soiltransmitted helminths using the Kato-Katz technique: What is the influence of stirring, storage time and storage temperature on stool sample egg counts? PLoS Negl Trop Dis. 2021 Jan 22;15(1):e0009032.
- 15. Bivins A, Bibby K. Wastewater Surveillance during Mass COVID-19 Vaccination on a College Campus. Environ Sci Technol Lett. 2021 Sep 14;8(9):792–8.
- 16. Liu J, Gratz J, Amour C, Kibiki G, Becker S, Janaki L, et al. A laboratory-developed TaqMan Array Card for simultaneous detection of 19 enteropathogens. J Clin Microbiol. 2013 Feb;51(2):472–80.
- Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019 Aug;37(8):852–7.
- 18. Marques BL, Brandao CU, Silva EF, Marques VA, Villela-Nogueira CA, Do OK, et al. Dried blood spot samples: optimization of commercial EIAs for hepatitis C antibody detection and stability under different storage conditions. J Med Virol. 2012 Oct;84(10):1600–7.
- 19. Parker SP, Cubitt WD. The use of the dried blood spot sample in epidemiological studies. J Clin Pathol. 1999 Sep;52(9):633–9.
- 20. Centers for Disease Control and Prevention Division of Parasitic Diseases and Malaria. Blood Collection and Dried Blood Spot Preparation. Atlanta, GA: Centers for Disease Control and Prevention; 2019. Report No.: ECL.DR.C.032.
- Lammie PJ, Moss DM, Brook Goodhew E, Hamlin K, Krolewiecki A, West SK, et al. Development of a new platform for neglected tropical disease surveillance. Int J Parasitol. 2012 Aug;42(9):797–800.
- Zambrano LD, Priest JW, Ivan E, Rusine J, Nagel C, Kirby M, et al. Use of Serologic Responses against Enteropathogens to Assess the Impact of a Point-of-Use Water Filter: A Randomized Controlled Trial in Western Province, Rwanda. Am J Trop Med Hyg. 2017 Sep;97(3):876–87.
- 23. Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med. 2001 Nov;345(18):1331–5.
- 4500-Cl CHLORINE (RESIDUAL). In: Standard Methods For the Examination of Water and Wastewater [Internet]. American Public Health Association; 2018 [cited 2021 Oct 11]. (Standard Methods for the Examination of Water and Wastewater). Available from: https://www.standardmethods.org/doi/abs/10.2105/SMWW.2882.078